Essential Role of the Adhesion Receptor LFA-1 for T Cell-Dependent Fulminant Hepatitis

Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant hepatitis. Activation of T cells is an initial and critical event in the pathogenesis of liver damage in autoimmune and viral hepatitis. The prec...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) Vol. 169; no. 12; pp. 7087 - 7096
Main Authors: Matsumoto, Goichi, Tsunematsu, Satoshi, Tsukinoki, Kei-ichi, Ohmi, Yasushi, Iwamiya, Mariko, Oliveira-dos-Santos, Antonio, Tone, Daisuke, Shindo, Junichi, Penninger, Josef M
Format: Journal Article
Language:English
Published: United States Am Assoc Immnol 15-12-2002
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant hepatitis. Activation of T cells is an initial and critical event in the pathogenesis of liver damage in autoimmune and viral hepatitis. The precise molecular mechanisms that induce T cell-mediated hepatocyte injury remain largely unclear. In mice, T cell-dependent hepatitis and acute liver damage can be modeled using ConA. In this study, we examined the role of the adhesion receptor LFA-1 in ConA-induced acute hepatic damage using LFA-1(-/-) (CD11a) mice. Massive liver cell apoptosis and metabolic liver damage were observed in LFA-1(+/+) mice following ConA injection. By contrast, LFA-1(-/-) mice were completely resistant to ConA-induced hepatitis and none of the LFA-1(-/-) mice showed any hepatic damage. Whereas activated hepatic T cells remained in the liver in LFA-1(+/+) mice, activated T cells were rapidly cleared from the livers of LFA-1(-/-) mice. Mechanistically, T cells from LFA-1(-/-) mice showed markedly reduced cytotoxicity toward liver cells as a result of impaired, activation-dependent adhesion. Importantly, adoptive transfer of hepatic T cells from LFA-1(+/+) mice, but not from LFA-1(-/-) mice, sensitized LFA-1(-/-) mice to ConA-induced hepatitis. Thus, LFA-1 expression on T cells is necessary and sufficient for T cell-mediated liver damage in vivo. These results provide the first genetic evidence on an adhesion receptor, LFA-1, that has a crucial role in fulminant hepatitis. These genetic data identify LFA-1 as a potential key target for the treatment of T cell-mediated hepatitis and the prevention of liver damage.
AbstractList Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant hepatitis. Activation of T cells is an initial and critical event in the pathogenesis of liver damage in autoimmune and viral hepatitis. The precise molecular mechanisms that induce T cell-mediated hepatocyte injury remain largely unclear. In mice, T cell-dependent hepatitis and acute liver damage can be modeled using ConA. In this study, we examined the role of the adhesion receptor LFA-1 in ConA-induced acute hepatic damage using LFA-1 super(-/-) (CD11a) mice. Massive liver cell apoptosis and metabolic liver damage were observed in LFA-1 super(+/+) mice following ConA injection. By contrast, LFA-1 super(-/-) mice were completely resistant to ConA-induced hepatitis and none of the LFA-1 super(-/-) mice showed any hepatic damage. Whereas activated hepatic T cells remained in the liver in LFA-1 super(+/+) mice, activated T cells were rapidly cleared from the livers of LFA-1 super(-/-) mice. Mechanistically, T cells from LFA-1 super(-/-) mice showed markedly reduced cytotoxicity toward liver cells as a result of impaired, activation-dependent adhesion. Importantly, adoptive transfer of hepatic T cells from LFA-1 super(+/+) mice, but not from LFA-1 super(-/-) mice, sensitized LFA-1 super(-/-) mice to ConA-induced hepatitis. Thus, LFA-1 expression on T cells is necessary and sufficient for T cell-mediated liver damage in vivo. These results provide the first genetic evidence on an adhesion receptor, LFA-1, that has a crucial role in fulminant hepatitis. These genetic data identify LFA-1 as a potential key target for the treatment of T cell-mediated hepatitis and the prevention of liver damage.
Abstract Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant hepatitis. Activation of T cells is an initial and critical event in the pathogenesis of liver damage in autoimmune and viral hepatitis. The precise molecular mechanisms that induce T cell-mediated hepatocyte injury remain largely unclear. In mice, T cell-dependent hepatitis and acute liver damage can be modeled using ConA. In this study, we examined the role of the adhesion receptor LFA-1 in ConA-induced acute hepatic damage using LFA-1−/− (CD11a) mice. Massive liver cell apoptosis and metabolic liver damage were observed in LFA-1+/+ mice following ConA injection. By contrast, LFA-1−/− mice were completely resistant to ConA-induced hepatitis and none of the LFA-1−/− mice showed any hepatic damage. Whereas activated hepatic T cells remained in the liver in LFA-1+/+ mice, activated T cells were rapidly cleared from the livers of LFA-1−/− mice. Mechanistically, T cells from LFA-1−/− mice showed markedly reduced cytotoxicity toward liver cells as a result of impaired, activation-dependent adhesion. Importantly, adoptive transfer of hepatic T cells from LFA-1+/+ mice, but not from LFA-1−/− mice, sensitized LFA-1−/− mice to ConA-induced hepatitis. Thus, LFA-1 expression on T cells is necessary and sufficient for T cell-mediated liver damage in vivo. These results provide the first genetic evidence on an adhesion receptor, LFA-1, that has a crucial role in fulminant hepatitis. These genetic data identify LFA-1 as a potential key target for the treatment of T cell-mediated hepatitis and the prevention of liver damage.
Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant hepatitis. Activation of T cells is an initial and critical event in the pathogenesis of liver damage in autoimmune and viral hepatitis. The precise molecular mechanisms that induce T cell-mediated hepatocyte injury remain largely unclear. In mice, T cell-dependent hepatitis and acute liver damage can be modeled using ConA. In this study, we examined the role of the adhesion receptor LFA-1 in ConA-induced acute hepatic damage using LFA-1(-/-) (CD11a) mice. Massive liver cell apoptosis and metabolic liver damage were observed in LFA-1(+/+) mice following ConA injection. By contrast, LFA-1(-/-) mice were completely resistant to ConA-induced hepatitis and none of the LFA-1(-/-) mice showed any hepatic damage. Whereas activated hepatic T cells remained in the liver in LFA-1(+/+) mice, activated T cells were rapidly cleared from the livers of LFA-1(-/-) mice. Mechanistically, T cells from LFA-1(-/-) mice showed markedly reduced cytotoxicity toward liver cells as a result of impaired, activation-dependent adhesion. Importantly, adoptive transfer of hepatic T cells from LFA-1(+/+) mice, but not from LFA-1(-/-) mice, sensitized LFA-1(-/-) mice to ConA-induced hepatitis. Thus, LFA-1 expression on T cells is necessary and sufficient for T cell-mediated liver damage in vivo. These results provide the first genetic evidence on an adhesion receptor, LFA-1, that has a crucial role in fulminant hepatitis. These genetic data identify LFA-1 as a potential key target for the treatment of T cell-mediated hepatitis and the prevention of liver damage.
Author Tone, Daisuke
Tsukinoki, Kei-ichi
Matsumoto, Goichi
Iwamiya, Mariko
Oliveira-dos-Santos, Antonio
Tsunematsu, Satoshi
Penninger, Josef M
Ohmi, Yasushi
Shindo, Junichi
Author_xml – sequence: 1
  fullname: Matsumoto, Goichi
– sequence: 2
  fullname: Tsunematsu, Satoshi
– sequence: 3
  fullname: Tsukinoki, Kei-ichi
– sequence: 4
  fullname: Ohmi, Yasushi
– sequence: 5
  fullname: Iwamiya, Mariko
– sequence: 6
  fullname: Oliveira-dos-Santos, Antonio
– sequence: 7
  fullname: Tone, Daisuke
– sequence: 8
  fullname: Shindo, Junichi
– sequence: 9
  fullname: Penninger, Josef M
BackLink https://www.ncbi.nlm.nih.gov/pubmed/12471145$$D View this record in MEDLINE/PubMed
BookMark eNpNkE1r3DAURUVJaCYf_yAErUI3nujJsiQvh0mmKQwUQtqtkO3njIJsOZbN0H9fDTOhXb27OPfyOJfkrA89EnILbCmYKB_eXdfNffBLkOUS-FIxrb6QBRQFy6Rk8owsGOM8AyXVBbmM8Z0xJhkXX8kFcKEARLEgv59ixH5y1tOX4JGGlk47pKtmh9GFnr5gjcMURrrdrDKgbUqvdI3eZ484YN-kLt3MvnO9TekZBzu5ycVrct5aH_HmdK_Ir83T6_o52_78_mO92ma1gHzKtFZtkzdcgKwZU0JVZdVUhS55q_OqyllVYlGUSktlCw2s1JIn2upWCV3qOr8i98fdYQwfM8bJdC7W6T3bY5ijAS1BMtAJFEewHkOMI7ZmGF1nxz8GmDn4NJ8-TfJpgJuDz1S7O-3PVYfNv9JJYAK-HYGde9vt3Ygmdtb7hIPZ7_f_b_0FRCyBJA
CitedBy_id crossref_primary_10_1016_j_jhep_2005_11_042
crossref_primary_10_1074_jbc_M407190200
crossref_primary_10_3181_0801_RM_15
crossref_primary_10_1111_j_1478_3231_2005_01137_x
crossref_primary_10_1016_j_imlet_2013_02_004
crossref_primary_10_1016_j_jcmgh_2020_12_003
crossref_primary_10_1371_journal_pone_0215557
crossref_primary_10_3390_cells9061471
crossref_primary_10_4049_jimmunol_0901221
crossref_primary_10_4049_jimmunol_176_8_4914
crossref_primary_10_1111_liv_12182
crossref_primary_10_1007_s00109_022_02215_1
crossref_primary_10_1189_jlb_0905527
crossref_primary_10_3390_molecules24061087
crossref_primary_10_3389_fvets_2022_960981
crossref_primary_10_1152_ajpgi_00184_2004
crossref_primary_10_2353_ajpath_2007_060690
crossref_primary_10_1177_0023677215572841
crossref_primary_10_1371_journal_pone_0090571
crossref_primary_10_1016_j_surg_2008_05_010
crossref_primary_10_1111_j_1476_5381_2011_01225_x
crossref_primary_10_1016_j_taap_2012_11_009
crossref_primary_10_1111_sji_12812
Cites_doi 10.1016/S1359-6101(00)00034-4
10.1002/(SICI)1521-4141(199812)28:12<4105::AID-IMMU4105>3.0.CO;2-8
10.4049/jimmunol.162.9.5094
10.1002/hep.510240338
10.1016/S0952-7915(98)80227-6
10.1016/S1089-3261(05)70117-3
10.1006/excr.1996.0351
10.4049/jimmunol.131.2.611
10.4049/jimmunol.160.12.5781
10.1073/pnas.040566697
10.4049/jimmunol.156.4.1587
10.1084/jem.191.1.105
10.1053/gast.1996.v111.pm8690213
10.4049/jimmunol.162.7.3753
10.4049/jimmunol.159.3.1418
10.1084/jem.183.4.1415
10.4049/jimmunol.159.3.1537
10.1146/annurev.immunol.14.1.207
10.1016/0092-8674(93)90134-C
10.1002/hep.1840210131
10.1172/JCI10613
10.4049/jimmunol.163.1.93
10.4049/jimmunol.166.10.5889
10.1111/j.1600-065X.1999.tb01336.x
10.1093/jnci/53.1.261
10.1016/S0753-3322(99)80096-1
10.1172/JCI115836
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
H94
DOI 10.4049/jimmunol.169.12.7087
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
AIDS and Cancer Research Abstracts
Immunology Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1550-6606
EndPage 7096
ExternalDocumentID 10_4049_jimmunol_169_12_7087
12471145
www169_12_7087
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
08R
2WC
34G
39C
3O-
53G
55
5GY
5RE
5VS
79B
85S
8RP
AALRV
AARDX
ABEFU
ABFLS
ABOCM
ABPPZ
ABPTK
ACGFS
ACIWK
ACNCT
ACPRK
ADACO
ADBBV
ADKFC
AENEX
AETEA
AFFNX
AFRAH
AJYGW
ALMA_UNASSIGNED_HOLDINGS
BAWUL
D0L
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
G8K
GJ
GX1
IH2
J5H
K-O
K78
KQ8
L7B
MVM
MYA
NEJ
O0-
OK1
P0W
P2P
PQEST
PQQKQ
R.V
RHF
RHI
RZQ
SJN
SKT
TWZ
VH1
WH7
WOQ
X
X7M
XJT
YCJ
ZA5
ZE2
ZGI
ZXP
---
-~X
.55
.GJ
18M
ABCQX
ABJNI
ACGFO
ADNWM
AFHIN
AFOSN
AHWXS
AI.
AIZAD
BTFSW
CGR
CUY
CVF
ECM
EIF
NPM
TR2
W8F
XSW
XTH
YHG
AAYXX
CITATION
7T5
H94
ID FETCH-LOGICAL-c413t-887fd3d2416c00747b9bdb5892f83bb30b9e5597867a58109862d24a8f74898c3
ISSN 0022-1767
IngestDate Fri Oct 25 02:41:05 EDT 2024
Thu Sep 26 18:30:18 EDT 2024
Sat Sep 28 08:33:29 EDT 2024
Tue Nov 10 19:47:59 EST 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c413t-887fd3d2416c00747b9bdb5892f83bb30b9e5597867a58109862d24a8f74898c3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://journals.aai.org/jimmunol/article-pdf/169/12/7087/1154033/7087.pdf
PMID 12471145
PQID 18616018
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_18616018
crossref_primary_10_4049_jimmunol_169_12_7087
pubmed_primary_12471145
highwire_smallpub1_www169_12_7087
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 20021215
2002-Dec-15
2002-12-15
PublicationDateYYYYMMDD 2002-12-15
PublicationDate_xml – month: 12
  year: 2002
  text: 20021215
  day: 15
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of immunology (1950)
PublicationTitleAlternate J Immunol
PublicationYear 2002
Publisher Am Assoc Immnol
Publisher_xml – name: Am Assoc Immnol
References 2022123116452662700_R26
2022123116452662700_R25
2022123116452662700_R24
2022123116452662700_R23
2022123116452662700_R29
2022123116452662700_R28
2022123116452662700_R27
2022123116452662700_R22
2022123116452662700_R21
2022123116452662700_R20
2022123116452662700_R8
2022123116452662700_R15
2022123116452662700_R7
2022123116452662700_R14
2022123116452662700_R13
2022123116452662700_R9
2022123116452662700_R12
2022123116452662700_R19
2022123116452662700_R18
2022123116452662700_R17
2022123116452662700_R16
2022123116452662700_R11
2022123116452662700_R10
2022123116452662700_R2
2022123116452662700_R1
2022123116452662700_R4
2022123116452662700_R3
2022123116452662700_R6
2022123116452662700_R5
References_xml – ident: 2022123116452662700_R1
  doi: 10.1016/S1359-6101(00)00034-4
– ident: 2022123116452662700_R15
  doi: 10.1002/(SICI)1521-4141(199812)28:12<4105::AID-IMMU4105>3.0.CO;2-8
– ident: 2022123116452662700_R25
  doi: 10.4049/jimmunol.162.9.5094
– ident: 2022123116452662700_R16
  doi: 10.1002/hep.510240338
– ident: 2022123116452662700_R18
  doi: 10.1016/S0952-7915(98)80227-6
– ident: 2022123116452662700_R2
  doi: 10.1016/S1089-3261(05)70117-3
– ident: 2022123116452662700_R6
  doi: 10.1006/excr.1996.0351
– ident: 2022123116452662700_R20
  doi: 10.4049/jimmunol.131.2.611
– ident: 2022123116452662700_R22
  doi: 10.4049/jimmunol.160.12.5781
– ident: 2022123116452662700_R24
  doi: 10.1073/pnas.040566697
– ident: 2022123116452662700_R28
  doi: 10.4049/jimmunol.156.4.1587
– ident: 2022123116452662700_R9
– ident: 2022123116452662700_R14
  doi: 10.1084/jem.191.1.105
– ident: 2022123116452662700_R8
  doi: 10.1053/gast.1996.v111.pm8690213
– ident: 2022123116452662700_R26
  doi: 10.4049/jimmunol.162.7.3753
– ident: 2022123116452662700_R11
  doi: 10.4049/jimmunol.159.3.1418
– ident: 2022123116452662700_R21
  doi: 10.1084/jem.183.4.1415
– ident: 2022123116452662700_R13
  doi: 10.4049/jimmunol.159.3.1537
– ident: 2022123116452662700_R17
  doi: 10.1146/annurev.immunol.14.1.207
– ident: 2022123116452662700_R29
  doi: 10.1016/0092-8674(93)90134-C
– ident: 2022123116452662700_R7
  doi: 10.1002/hep.1840210131
– ident: 2022123116452662700_R10
  doi: 10.1172/JCI10613
– ident: 2022123116452662700_R12
  doi: 10.4049/jimmunol.163.1.93
– ident: 2022123116452662700_R19
– ident: 2022123116452662700_R27
  doi: 10.4049/jimmunol.166.10.5889
– ident: 2022123116452662700_R3
  doi: 10.1111/j.1600-065X.1999.tb01336.x
– ident: 2022123116452662700_R23
  doi: 10.1093/jnci/53.1.261
– ident: 2022123116452662700_R4
  doi: 10.1016/S0753-3322(99)80096-1
– ident: 2022123116452662700_R5
  doi: 10.1172/JCI115836
SSID ssj0006024
Score 1.8799865
Snippet Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in fulminant...
Abstract Viral hepatitis affects more than 2 billion people worldwide. In particular, no effective treatment exists to abrogate death and liver damage in...
SourceID proquest
crossref
pubmed
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 7087
SubjectTerms Adoptive Transfer
Animals
Antibodies, Monoclonal - administration & dosage
Antigens - biosynthesis
Antigens, Surface
Cell Adhesion - genetics
Cell Adhesion - immunology
Cell Line
Chemical and Drug Induced Liver Injury - etiology
Chemical and Drug Induced Liver Injury - genetics
Chemical and Drug Induced Liver Injury - immunology
Chemical and Drug Induced Liver Injury - prevention & control
Concanavalin A - toxicity
Cytotoxicity, Immunologic - genetics
Injections, Intravenous
Intercellular Adhesion Molecule-1 - immunology
Killer Cells, Natural - immunology
Killer Cells, Natural - metabolism
Killer Cells, Natural - transplantation
Lectins, C-Type
Liver - immunology
Liver - pathology
Lymphocyte Activation - genetics
Lymphocyte Activation - immunology
Lymphocyte Function-Associated Antigen-1 - biosynthesis
Lymphocyte Function-Associated Antigen-1 - genetics
Lymphocyte Function-Associated Antigen-1 - physiology
Mice
Mice, Inbred C57BL
Mice, Knockout
NK Cell Lectin-Like Receptor Subfamily B
Protein Biosynthesis
Proteins
Receptors, Antigen, T-Cell, alpha-beta - biosynthesis
T-Lymphocyte Subsets - immunology
T-Lymphocyte Subsets - metabolism
T-Lymphocyte Subsets - transplantation
Title Essential Role of the Adhesion Receptor LFA-1 for T Cell-Dependent Fulminant Hepatitis
URI http://www.jimmunol.org/cgi/content/abstract/169/12/7087
https://www.ncbi.nlm.nih.gov/pubmed/12471145
https://search.proquest.com/docview/18616018
Volume 169
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZoEYgLgvJankaCUxWad5xj1c2qiG2RIEW9WU7sqKtuk4okWvHvmbHz2goEHLhEGyuJNzOf7JnJzHyEvHNyOxSxz6zCK8BByfPQ0qe-CAqZCy8QOkH2-Gt0es7miZ-MX_DHsf-qaRgDXWPl7D9oe3goDMBv0DkcQetw_Cu9JzWWE2Ec_EuXOKiLR-SFwrgYmonqGvzs_eXi0HJ0kmG6f6TWa2ve0eE2mBBiEmRgU8KE62ZVT23YsZrMNJzAChPTyem9_l5mT6ILJ6KBl680V9NI45XWbYm9Yut2K_gKw5ersrq8QZB9cbUaN4o-QKG5UkyJ5qRgwIkM68aw6BqClh5d7mQNjexuC1bdqaG8vbnW--Db4FrfveUHeCIGdse7p621Tz_zxdlyydPkPN0ht11YlTD_c_7x07Bth7br963l8d-aOkuc5eBXc2zbMX1v6d_7KdpeSR-Q-52C6KFByENyS5V75I6hHv2xR-6edEkVj8i3ATIUIUOrggJkaA8Z2kOGashQgAxN6TZk6AAZOkDmMTlbJOnRsdXRbVg5WDKNBdtNIT0JJl2Ya16FLM5kFrDYLZiXZZ6dxQr9TxZGImCOHYMzDFcLVmAHI5Z7T8huWZXqGaGxYJH0fMkiIX2wmZmIRF64SBUg3SJXM2L1wuPXpqsKB28Uhc17YXMQNndcjsKekbe9hHl9JdZrkKzDN5vN1jVvetFzWCLxu5coVdXW3GGhE9oOm5GnRiPjnC7YZo4fPP_jvS_IvRHbL8lu871Vr8hOLdvXGkY_AUgKiGc
link.rule.ids 315,782,786,27935,27936
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Essential+Role+of+the+Adhesion+Receptor+LFA-1+for+T+Cell-Dependent+Fulminant+Hepatitis&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Matsumoto%2C+G&rft.au=Tsunematsu%2C+S&rft.au=Tsukinoki%2C+K&rft.au=Ohmi%2C+Y&rft.date=2002-12-15&rft.issn=0022-1767&rft.volume=169&rft.issue=12&rft.spage=7087&rft.epage=7096&rft_id=info:doi/10.4049%2Fjimmunol.169.12.7087&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon